Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report.

ABSTRACT: Risk stratification for acute myeloid leukemia (AML) uses molecular and cytogenetic abnormalities identified at diagnosis. Response to therapy informs risk, and morphology continues to be used more frequently than flow cytometry. Herein, the largest cohort of pediatric patients prospectively assessed for measurable residual disease (MRD) by flow cytometry (N = 784) is reported. The "difference from normal" (ΔN) technique was applied: 31% of all patients tested positive (AML range, 0.02% to 91%) after the first course of treatment on Children's Oncology Group study AAML0531. Detection of MRD following initial chemotherapy proved the strongest predicator of overall survival (OS) in univariable and multivariable analyses, and was predictive of relapse risk, disease-free survival, and treatmen

SUBMITTER: Brodersen LE 

PROVIDER: S-EPMC7594384 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature